drugset / Trial / NCT00410904

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

NCT00410904

Phase 2 Completed 60 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well giving AZD2171 together with pemetrexed disodium works in treating patients with relapsed non-small cell lung cancer. AZD2171 and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. AZD2171 may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving AZD2171 together with pemetrexed disodium may kill more tumor cells.

Timeline

Start
2006-10
Primary completion
2013-07
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cediranib Small molecule Oral
Subject Pemetrexed Small molecule Intravenous